BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Proud, P. C., Tsitoura, D., Watson, R. J., Chua, B. Y., Aram, M. J., & Bewley, K. R., et al. (2020). Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. bioRxiv. Added by: Dr. Enrique Feoli (11/11/2020, 17:49) Last edited by: Dr. Enrique Feoli (11/11/2020, 17:50) |
 |
| Resource type: Journal Article DOI: 10.1101/2020.09.25.309914 BibTeX citation key: Proud2020 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Inmunidad de mucosas Creators: Aram, Bartlett, Bewley, Carroll, Cavell, Chua, Cobb, Demaison, Dowall, Fotheringham, Ho, Jackson, Lucas, Mercuri, Ngabo, Proud, Rayner, Ryan, Slack, Thomas, Tsitoura, Wand, Watson, Yeates Collection: bioRxiv |
Views: 3/243
|
| Abstract |
|
Respiratory viruses such as coronaviruses represent major ongoing global threats, causing epidemics and pandemics with huge economic burden. Rapid spread of virus through populations poses an enormous challenge for outbreak control. Like all respiratory viruses, the most recent novel human coronavirus SARS-CoV-2, initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat. The results of our study support clinical development of a therapy based on prophylactic TLR2/6 innate immune activation in the URT to reduce SARS-CoV-2 transmission and provide protection against COVID-19.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |